Prima Biomed Ltd. (Nasdaq: PBMD) reported positive results from a Phase II clinical trial of its ovarian cancer treatment CAN-003 sending the stock price soaring $4.50 to $6.10.
Positive test results for Prima Biomed
May 20, 2015 at 13:03 PM EDT